Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Q3 2023 Earnings Presentation
24 slides from Expres2ion Biotech Holding Ab's earnings presentation, Nov 16, 2023
Slide 1: Presentation of Q3 2023 Results
Click to edit Master title style Presentation of Q3 2023 Results Innovative vaccines for a healthier world 16 November 2023 Hosted by ExpreS2ion Biotech Holding AB Org. Nr. 559033-3729 Innovative vaccines for a healthier world
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company”). Neither shall the presentation or any part of i
Slide 3: Management Discussion and Analysis
Management Discussion and Analysis Innovative vaccines for a healthier world |3
Slide 4: ABNCoV2 COVID-19 Booster Vaccine
COVID-19 ABNCoV2 COVID-19 Booster Vaccine A unique vaccine based on ExpreS2™-made antigen and AdaptVac’s VLP technology • Phase I, started 2020, completed 2021, conducted under PREVENT- nCoV consortia (biotech and academia partners) • Phase II, started 2021, completed 2022, sponsored by Bavarian Nor
Slide 5: Q3 update on ABNCoV2 Phase III
COVID-19 Q3 update on ABNCoV2 Phase III • Bavarian Nordic (BN) reported the • Reduced options for raising capital secondary endpoint results for their • Assumptions for TO8 warrant Phase III clinical trial subscription proceeds changed: • Did not successfully meet secondary • SEK 54.5M prospects at
Slide 6: Promising preclinical data package
BREAST CANCER Promising preclinical data package • We have developed ES2B-C001, a HER2 VLP vaccine candidate to be tested in HER2+ breast cancer patients • ES2B-C001 completely prevents tumor development after only 2 vaccinations in mice • The vaccine induces strong and persistent antibody responses
Slide 7: Strategic review
Strategic review Announced in August 2023 • Strategic evaluation of ES2B-C001 • Certain activities to advance towards CTA readiness to continue, including the ongoing GLP preclinical safety toxicology study • Investigating strategic options • Initiating a cost reduction program • Near-term cash posi
Slide 8: Leadership
Leadership Greater than 200 years deep professional experience to support a pipeline-driven business Management Team Board of Directors Innovative vaccines for a healthier world |8
Slide 9: Outcome of strategic review (I)
Outcome of strategic review (I) Cost reductions Cut over SEK 50 million in Reductions primarily in Cash runway into 2025 costs R&D, personnel and facilities Innovative vaccines for a healthier world |9
Slide 10: Outcome of strategic review (II)
Outcome of strategic review (II) ES2B-C001 breast cancer vaccine candidate Halted plan for CRO-driven Phase I clinical trial Continuing preparations for advancing into clinical development Preclinical safety studies GMP manufacturing Regulatory alignment Evaluating other development options Investig
Slide 11: Outcome of strategic review (III)
Outcome of strategic review (III) Other activities, including other pipeline assets and platform development Enhancing focus on certain Qualification of various Saying “no” to lower priority exploratory pipeline projects factors driving prioritization activities Timeline leading to value CRO project
Slide 12: Other Q3 updates
MALARIA Other Q3 updates Updates to Malaria pipeline Candidate in Phase II clinical trial Candidates in Phase I clinical trials New clinical trials expected to be initiated over the next year Discontinuing updates on two programs Innovative vaccines for a healthier world | 12
Slide 13: Pipeline
Pipeline Status at last update Progress since last update Updates to legacy programs No further update to be provided Pre-clinical Disease Project / Target Discovery Pharmacology cGMP / Tox Phase 1 Phase 2 Phase 3 Market potential MALARIA >1.8 billion EUR Blood-Stage RH5.1 IIb Blood-Stage RH5.2-VLP
Slide 14: Pipeline: Legacy programs
Pipeline Legacy programs Pre-clinical Disease Project / Target Discovery Pharmacology cGMP / Tox Phase 1 Phase 2 Phase 3 Market potential MALARIA >1.8 billion EUR Blood-Stage RH5.1 IIb Blood-Stage RH5.2-VLP Ib Placenta-Borne VAR2CSA1 Ib Transmission Pfs 48/45 Ia Blood-Stage RH5.1 + R78C Ia Blood-Sta
Slide 15: Pipeline: Focus programs
Pipeline Focus programs Pre-clinical Disease Project / Target Discovery Pharmacology cGMP / Tox Phase 1 Phase 2 Phase 3 Market potential COVID-191 ABNCoV2/SARS-CoV-2 cVLP > 10 billion EUR BREAST CANCER ES2B-C001/Her2 cVLP > 10 billion EUR INFLUENZA2 MucoVax > 7 billion EUR CMV3 ES2B-I002 > 2 billion
Slide 16: Advancing focus pipeline towards key catalysts
Advancing focus pipeline towards key catalysts 2022 2023 2024 2025+ ✓ ✓ ✓ BN Phase II 12-month durability data BN BN Phase II trial BN Phase III trial readout H1 initiation Q3 COVID-19 ✓ Phase III initial readout ABNCoV2 Phase III milestone related income ✓ Phase III secondary readout X Bavarian Nor
Slide 17: Financial Results
Financial Results Innovative vaccines for a healthier world | 17
Slide 18: Operating income
FINANCE Operating income Operating income, SEK ‘000s Net sales, SEK ‘000s Other operating income, SEK ‘000s 6,000 6,000 1,200 Net sales Other operating income 5,000 5,000 1,000 4,000 = 4,000 800 3,000 3,000 + 600 2,000 2,000 400 1,000 1,000 200 0 0 0 1Q21 3Q21 1Q22 3Q22 1Q23 3Q23 1Q21 3Q21 1Q22 3Q22
Slide 19: Operating costs
FINANCE Operating costs Operating costs, SEK ‘000s 0 -8,000 -16,000 -24,000 -32,000 -40,000 -48,000 -56,000 -64,000 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 Innovative vaccines for a healthier world | 19
Slide 20: Operating costs composition
FINANCE Operating costs composition SEK ‘000s R&D costs (external) Personnel costs excl. vesting of share-based compensation 0 0 -15,000 -5,000 -30,000 -10,000 Decreasing; will decrease further Volatile & dependent upon due to cost reductions; sensitive pipeline activities to FX and inflation -45,00
Slide 21: Profit / loss for the period
FINANCE Profit / loss for the period 3Q profit / loss, SEK ‘000s YTD profit / loss, SEK ‘000s 2022 2023 2022 2023 0 0 -7,000 -17,000 -14,000 -34,000 -21,000 -51,000 -21,826 -28,000 -68,000 -29% -70,072 +12% -30,701 -78,172 -35,000 -85,000 Innovative vaccines for a healthier world | 21
Slide 22: Cash development year-to-date
FINANCE Cash development year-to-date SEK millions 180 50 150 120 111 90 4 77 -88 60 30 0 December 2022 New Capital Operations and Currency changes September 2023 Investment Activities Innovative vaccines for a healthier world | 22
Slide 23: Cash balance, 1Q21 – 3Q23 quarterly
FINANCE Cash balance, 1Q21 – 3Q23 quarterly SEK millions 200 175 168 150 150 142 139 125 125 108 111 100 88 83 77 75 72 50 25 0 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 Innovative vaccines for a healthier world | 23
Slide 24: Thank you
Thank you investor@expres2ionbio.com Innovative vaccines for a healthier world | 24
ExpreS2ion Biotech Holding — Q3 2023 Earnings Presentation on 6ix